Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
Brain and Behavior · 2023
DOI: 10.1002/brb3.3151 ↗At a glance
Systematische Übersicht in Brain and Behavior, 2023. Written by Gustav Cedergren Weber and 4 co-authors. Institution: Division of Neurology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden. Major MEDLINE topics: Parkinsonian Disorders, Brain Neoplasms, Astrocytoma, Paraneoplastic Syndromes. Cited 8 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Secondary tumoral parkinsonism is a rare phenomenon that develops as a direct or indirect result of brain neoplasms or related conditions.
Objectives
The first objective was to explore to what extent brain neoplasms, cavernomas, cysts, paraneoplastic syndromes (PNSs), and oncological treatment methods cause parkinsonism. The second objective was to investigate the effect of dopaminergic therapy on the symptomatology in patients with tumoral parkinsonism.
Methods
A systematic literature review was conducted in the databases PubMed and Embase. Search terms like “secondary parkinsonism,” “astrocytoma,” and “cranial irradiation” were used. Articles fulfilling inclusion criteria were included in the review.
Results
Out of 316 identified articles from the defined database search strategies, 56 were included in the detailed review. The studies, which were mostly case reports, provided research concerning tumoral parkinsonism and related conditions. It was found that various types of primary brain tumors, such as astrocytoma and meningioma, and more seldom brain metastases, can cause tumoral parkinsonism. Parkinsonism secondary to PNSs, cavernomas, cysts, as well as oncological treatments was reported. Twenty‐five of the 56 included studies had tried initiating dopaminergic therapy, and of these 44% reported no, 48% low to moderate, and 8% excellent effect on motor symptomatology.
Conclusion
Brain neoplasms, PNSs, certain intracranial malformations, and oncological treatments can cause parkinsonism. Dopaminergic therapy has relatively benign side effects and may relieve motor and nonmotor symptomatology in patients with tumoral parkinsonism. Dopaminergic therapy, particularly levodopa, should therefore be considered in patients with tumoral parkinsonism.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Neurology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.
- Department of Neurology, Rehabilitation Medicine, Memory and Geriatrics, Skåne University Hospital, Lund, Sweden.
- Division of Neurosurgery, Department of Clinical Sciences, Kamprad laboratory, Lund University, Lund, Sweden.
- Department of Neurosurgery, Skåne University Hospital, Lund, Sweden.
ORCID profiles: Gustav Cedergren Weber, Jonathan Timpka, Anna Rydelius, Johan Bengzon, Per Odin
Cite
APA
Cedergren Weber, G., Timpka, J., Rydelius, A., Bengzon, J., & Odin, P. (2023). Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment. Brain and Behavior. https://doi.org/10.1002/brb3.3151
Vancouver
Cedergren Weber G, Timpka J, Rydelius A, Bengzon J, Odin P. Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment. Brain and Behavior. 2023. doi:10.1002/brb3.3151
BibTeX
@article{CedergrenWeber2023,
author = {Cedergren Weber, Gustav and Timpka, Jonathan and Rydelius, Anna and Bengzon, Johan and Odin, Per},
title = {Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment},
journal = {Brain and Behavior},
year = {2023},
doi = {10.1002/brb3.3151}
}
EUVIMED